M07

Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically

This standard covers reference methods for determining minimal inhibitory concentrations of aerobic bacteria by broth macrodilution, broth microdilution, and agar dilution.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org
Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically

Melvin P. Weinstein, MD
Jean B. Patel, PhD, D(ABMM)
Carey-Ann Burnham, PhD, D(ABMM)
Shelley Campeau, PhD, D(ABMM)
Patricia S. Conville, MS, MT(ASCP)
Christopher Doern, PhD, D(ABMM)
George M. Eliopoulos, MD
Marcelo F. Galas
Romney M. Humphries, PhD, D(ABMM)
Stephen G. Jenkins, PhD, D(ABMM), F(AAM)
Susan M. Kircher, MS, MT(ASCP)
James S. Lewis II, PharmD, FIDSA

Brandi Limbago, PhD
Amy J. Mathers, MD, D(ABMM)
Tony Mazzulli, MD, FACP, FRCP(C)
Susan D. Munro, CLS, MT(ASCP)
Margaret Ordoñez Smith de Danies, PhD
Robin Patel, MD
Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA
Michael Satlin, MD, MS
Jana M. Swenson, MMSc
Alexandra Wong, BS, MT(ASCP), SM
Wayne F. Wang, MD, PhD
Barbara L. Zimmer, PhD

Abstract

Antimicrobial susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism’s identity. Susceptibility tests are most often indicated when the causative organism is thought to belong to a species capable of exhibiting resistance to commonly used antimicrobial agents.

Various laboratory methods can be used to measure the in vitro susceptibility of bacteria to antimicrobial agents. Clinical and Laboratory Standards Institute standard M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically describes standard broth dilution (macrodilution and microdilution [the microdilution method described in M07 is the same methodology outlined in ISO 20776-1]) and agar dilution techniques, and it includes a series of procedures to standardize the way the tests are performed. The performance, applications, and limitations of the current CLSI-recommended methods are also described.

The supplemental information (M100^2 tables) used with this standard represents the most current information for drug selection, interpretation, and quality control using the procedures standardized in M07.

Committee Membership

Consensus Council

Carl D. Mottram, RRT, RPFT, FAARC
Chairholder
Mayo Clinic
USA

Dennis J. Ernst, MT(ASCP), NCPT(NCCT)
Vice-Chairholder
Center for Phlebotomy Education
USA

J. Rex Astles, PhD, FACB, DABCC
Centers for Disease Control and Prevention
USA

Lucia M. Berte, MA, MT(ASCP)SBB, DLM, CQA(ASQ)CMQ/OE
Laboratories Made Better!
USA

Karen W. Dyer, MT(ASCP), DLM
Centers for Medicare & Medicaid Services
USA

Thomas R. Fritsche, MD, PhD, FCAP, FIDSA
Marshfield Clinic
USA

Mary Lou Gantzer, PhD, FACB
BioCore Diagnostics
USA

Loralie J. Langman, PhD, DABCC, FACB, F-ABFT
Mayo Clinic
USA

Ross J. Molinaro, PhD, MLS(ASCP)CM, DABCC, FACB
Siemens Healthcare Diagnostics, Inc.
USA

Joseph Passarelli
Roche Diagnostics Corporation
USA

Andrew Quintenz
Bio-Rad Laboratories, Inc.
USA

Robert Rej, PhD
New York State Department of Health – Wadsworth Center
USA

Zivana Tezak, PhD
FDA Center for Devices and Radiological Health
USA

Subcommittee on Antimicrobial Susceptibility Testing

Melvin P. Weinstein, MD
Chairholder
Rutgers Robert Wood Johnson Medical School
USA

Jean B. Patel, PhD, D(ABMM)
Vice-Chairholder
Centers for Disease Control and Prevention
USA

George M. Eliopoulos, MD
Beth Israel Deaconess Medical Center
USA

Marcelo F. Galas
Pan American Health Organization
USA

Romney M. Humphries, PhD, D(ABMM)
Accelerate Diagnostics
USA

Stephen G. Jenkins, PhD, D(ABMM), F(AAM)
Weill Cornell Medicine
USA

James S. Lewis II, PharmD, FIDSA
Oregon Health and Science University
USA

Brandi Limbago, PhD
Centers for Disease Control and Prevention
USA

Tony Mazzulli, MD, FACP, FRCP(C)
Mount Sinai Hospital
Canada

Robin Patel, MD
Mayo Clinic
USA

Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA
Cleveland Clinic
USA

Michael Satlin, MD, MS
New York Presbyterian Hospital
USA

Barbara L. Zimmer, PhD
Beckman Coulter – West Sacramento
USA

Amy J. Mathers, MD, D(ABMM)
University of Virginia Medical Center
USA
### Working Group on M02/M07 Revision

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carey-Ann Burnham, PhD, D(ABMM)</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Co-Chairholder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Washington University School of Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susan D. Munro, CLS, MT(ASCP)</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Co-Chairholder</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christopher Doern, PhD, D(ABMM)</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Committee Secretary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virginia Commonwealth University Health System</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>George M. Eliopoulos, MD</td>
<td>Amy J. Mathers, MD, D(ABMM)</td>
<td>USA</td>
</tr>
<tr>
<td>Co-Chairholder</td>
<td>University of Virginia Medical Center</td>
<td></td>
</tr>
<tr>
<td>Beth Israel Deaconess Medical Center</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>James S. Lewis II, PharmD, FIDSA</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Co-Chairholder</td>
<td>Hartford Hospital</td>
<td></td>
</tr>
<tr>
<td>Oregon Health and Science University</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karen Bush, PhD</td>
<td>Robin Patel, MD</td>
<td>USA</td>
</tr>
<tr>
<td>Committee Secretary</td>
<td>Mayo Clinic</td>
<td></td>
</tr>
<tr>
<td>Indiana University</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marcelo F. Galas</td>
<td>Audrey N. Schuetz, MD, MPH, D(ABMM)</td>
<td>USA</td>
</tr>
<tr>
<td>Pan American Health Organization</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patricia S. Conville, MS, MT(ASCP)</td>
<td>Margaret Ordoñez Smith de Danies, PhD</td>
<td>USA</td>
</tr>
<tr>
<td>FDA Center for Devices and Radiological Health</td>
<td>Microbiology Institute of Colombia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dwight J. Hardy, PhD</td>
<td>USA</td>
</tr>
<tr>
<td>University of Rochester Medical Center</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susan M. Kircher, MS, MT(ASCP)</td>
<td>Alexandra Wong, BS, MT(ASCP), SM</td>
<td>USA</td>
</tr>
<tr>
<td>BD Diagnostic Systems</td>
<td>FDA Center for Devices and Radiological Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simone M. Shurland</td>
<td>Hui Wang, MD</td>
<td>USA</td>
</tr>
<tr>
<td>FDA Center for Devices and Radiological Health</td>
<td>Peking University People’s Hospital</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patricia S. Conville, MS, MT(ASCP)</td>
<td>Samir Patel, PhD, FCCM, D(ABMM)</td>
<td>USA</td>
</tr>
<tr>
<td>FDA Center for Devices and Radiological Health</td>
<td>Public Health Ontario</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marcia G. Silber, CLS, MT(ASCP)</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Committee Secretary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virginia Commonwealth University Health System</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wayne F. Wang, MD</td>
<td>Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA</td>
<td>USA</td>
</tr>
<tr>
<td>Emory University Hospital</td>
<td>Cleveland Clinic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barbara L. Zimmer, PhD</td>
<td>Virginia M. Pierce, MD</td>
<td>USA</td>
</tr>
<tr>
<td>Beckman Coulter – West Sacramento</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Margaret Ordoñez Smith de Danies, PhD</td>
<td>Samir Patel, PhD, FCCM, D(ABMM)</td>
<td>USA</td>
</tr>
<tr>
<td>Microbiology Institute of Colombia</td>
<td>Public Health Ontario</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dwight J. Hardy, PhD</td>
<td>Kristie Johnson, PhD, D(ABMM)</td>
<td>USA</td>
</tr>
<tr>
<td>University of Maryland, Baltimore</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hui Wang, MD</td>
<td>Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA</td>
<td>USA</td>
</tr>
<tr>
<td>Peking University People’s Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alex S. Wong, BS, MT(ASCP), SM</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>FDA Center for Devices and Radiological Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joseph Kuti, PharmD</td>
<td>Samir Patel, PhD, FCCM, D(ABMM)</td>
<td>USA</td>
</tr>
<tr>
<td>Hartford Hospital</td>
<td>Public Health Ontario</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virginia M. Pierce, MD</td>
<td>Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA</td>
<td>USA</td>
</tr>
<tr>
<td>Massachusetts General Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Samir Patel, PhD, FCCM, D(ABMM)</td>
<td>Samir Patel, PhD, FCCM, D(ABMM)</td>
<td>USA</td>
</tr>
<tr>
<td>Public Health Ontario</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Working Group on AST Breakpoints

### Working Group on Methods Application and Interpretation
### Working Group on Methods Development and Standardization

<table>
<thead>
<tr>
<th>Co-Chairholder</th>
<th>William B. Brasso, BS</th>
<th>Romney M. Humphries, PhD, D(ABMM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Rochester Medical Center</td>
<td>BD Diagnostic Systems USA</td>
<td>Accelerate Diagnostics USA</td>
</tr>
<tr>
<td>Co-Chairholder</td>
<td>Jennifer Dien Bard, PhD, D(ABMM), FCCM USA</td>
<td>Laura M. Koeth, MT(ASCP) Laboratory Specialists, Inc. USA</td>
</tr>
<tr>
<td>Beckman Coulter – West Sacramento</td>
<td>Children’s Hospital Los Angeles USA</td>
<td>Ribhi M. Shawar, PhD, D(ABMM) FDA Center for Devices and Radiological Health USA</td>
</tr>
</tbody>
</table>

### Working Group on Outreach

<table>
<thead>
<tr>
<th>Co-Chairholder</th>
<th>April Abbott, PhD, D(ABMM)</th>
<th>Deaconess Hospital Laboratory USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Audrey N. Schuetz, MD, MPH, D(ABMM)</td>
<td>April Bobenchik, PhD, D(ABMM)</td>
<td>Lifespan Academic Medical Center USA</td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td>Angella Charnot-Katsikas, MD</td>
<td>The University of Chicago USA</td>
</tr>
<tr>
<td>Stella Antonara, PhD</td>
<td>Marcelo F. Galas</td>
<td>Pan American Health Organization USA</td>
</tr>
</tbody>
</table>

### Working Group on Quality Control

<table>
<thead>
<tr>
<th>Co-Chairholder</th>
<th>Kerian K. Grande Roche, PhD</th>
<th>Chris Pillar, PhD Micromyx, LLC USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria M. Traczewski, BS, MT(ASCP)</td>
<td>Dana C. Dressel, MT(ASCP) International Health Management Associates, Inc. USA</td>
<td>Elizabeth Palavecino, MD Wake Forest Baptist Medical Center USA</td>
</tr>
<tr>
<td>The Clinical Microbiology Institute</td>
<td>Janet A. Hindler, MCLS, MT(ASCP) USA</td>
<td>Mary K. York, PhD, D(ABMM) MKY Microbiology Consulting USA</td>
</tr>
<tr>
<td>JMI Laboratories</td>
<td>Michael D. Huband, BS Committee Secretary</td>
<td>USA</td>
</tr>
<tr>
<td>USA</td>
<td>USA</td>
<td>USA</td>
</tr>
<tr>
<td>Patricia S. Conville, MS, MT(ASCP)</td>
<td>USA</td>
<td>USA</td>
</tr>
<tr>
<td>FDA Center for Devices and Radiological Health</td>
<td>BD Diagnostic Systems USA</td>
<td>Erika Matuschek, PhD ESCMID Sweden</td>
</tr>
</tbody>
</table>
Working Group on Text and Tables

Shelley Campeau, PhD, D(ABMM)  
Co-Chairholder  
UCLA Medical Center  
USA

Jana M. Swenson, MMSc  
Co-Chairholder  
USA

Carey-Ann Burnham, PhD, D(ABMM)  
Committee Secretary  
Washington University School of Medicine  
USA

Melissa Jones, MT(ASCP), CLS  
UNC Healthcare  
USA

Expert Panel on Microbiology

Acknowledgment for the Expert Panel on Microbiology

CLSI, the Consensus Council, and the Subcommittee on Antimicrobial Susceptibility Testing gratefully acknowledge the Expert Panel on Microbiology for serving as technical advisors and subject matter experts during the development of this standard.

Expert Panel on Microbiology

Richard B. Thomson Jr., PhD, D(ABMM), FAAM  
Chairholder  
Evanston Hospital, NorthShore University HealthSystem  
USA

Mary Jane Ferraro, PhD, MPH  
Vice-Chairholder  
Massachusetts General Hospital and Harvard Medical School  
USA

Lynette Y. Berkeley, PhD, MT(ASCP)  
FDA Center for Drug Evaluation and Research  
USA

Carey-Ann Burnham, PhD, D(ABMM)  
Washington University School of Medicine  
USA

German Esparza, BSc  
Proasecal SAS  
Colombia

Mark G. Papich, DVM, MS  
College of Veterinary Medicine, North Carolina State University  
USA

Jean B. Patel, PhD, D(ABMM)  
Centers for Disease Control and Prevention  
USA

Peggy Kohner, BS, MT(ASCP)  
Mayo Clinic  
USA

Dyan Luper, BS, MT(ASCP), SM, MB  
BD Diagnostic Systems  
USA

L. Barth Reller, MD  
Duke University School of Medicine  
USA

Flavia Rossi, MD, PhD  
University of São Paulo  
Brazil

Dale A. Schwab, PhD, D(ABMM), CM  
Quest Diagnostics Nichols Institute  
USA

Richard B. Thomson, Jr., PhD, D(ABMM), FAAM  
Evanston Hospital, NorthShore University HealthSystem  
USA

Maria M. Traczewski, BS, MT(ASCP)  
The Clinical Microbiology Institute  
USA

Nancy E. Watz, MS, MT(ASCP), CLS  
Stanford Health Care  
USA

Mary K. York, PhD, D(ABMM)  
MKY Microbiology Consulting  
USA

Peggy Kohner, BS, MT(ASCP)  
Mayo Clinic  
USA

Linda M. Mann, PhD, D(ABMM)  
University HealthSystem  
USA

Susan D. Munro, CLS, MT(ASCP)  
USA

L. Barth Reller, MD  
Duke University School of Medicine  
USA

Flavia Rossi, MD, PhD  
University of São Paulo  
Brazil

Dale A. Schwab, PhD, D(ABMM), CM  
Quest Diagnostics Nichols Institute  
USA

Richard B. Thomson, Jr., PhD, D(ABMM), FAAM  
Evanston Hospital, NorthShore University HealthSystem  
USA

Maria M. Traczewski, BS, MT(ASCP)  
The Clinical Microbiology Institute  
USA

Nancy E. Watz, MS, MT(ASCP), CLS  
Stanford Health Care  
USA

Mary K. York, PhD, D(ABMM)  
MKY Microbiology Consulting  
USA

Peggy Kohner, BS, MT(ASCP)  
Mayo Clinic  
USA

Linda M. Mann, PhD, D(ABMM)  
University HealthSystem  
USA

Susan D. Munro, CLS, MT(ASCP)  
USA

L. Barth Reller, MD  
Duke University School of Medicine  
USA

Flavia Rossi, MD, PhD  
University of São Paulo  
Brazil

Dale A. Schwab, PhD, D(ABMM), CM  
Quest Diagnostics Nichols Institute  
USA

Richard B. Thomson, Jr., PhD, D(ABMM), FAAM  
Evanston Hospital, NorthShore University HealthSystem  
USA

Maria M. Traczewski, BS, MT(ASCP)  
The Clinical Microbiology Institute  
USA

Nancy E. Watz, MS, MT(ASCP), CLS  
Stanford Health Care  
USA

Mary K. York, PhD, D(ABMM)  
MKY Microbiology Consulting  
USA
Acknowledgments

CLSI, the Consensus Council, the Subcommittee on Antimicrobial Susceptibility Testing, and the Working Group on M02/M07 Revision gratefully acknowledge the following volunteers for their important contributions to the development of this standard:

Patricia Bradford, PhD  Jennifer Dien Bard, PhD, D(ABMM), FCCM  Beth P. Goldstein, PhD
Antimicrobial Development  Children’s Hospital Los Angeles  Beth Goldstein Consultant
Specialists, LLC  USA

Karen Bush, PhD  Beth P. Goldstein
Indiana University  Beth Goldstein Consultant
USA

Darcie E. Carpenter, PhD, CIC, CEM  Audrey N. Schuetz, MD, MPH, D(ABMM)  Barbara L. Zimmer, PhD
Beckman Coulter, Inc.  Mayo Clinic  Beckman Coulter – West Sacramento
USA  USA  USA

Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA  Matthew A. Wikler, MD, FIDSA, MBA
Cleveland Clinic  IDTD Consulting
USA  USA

USA
Contents

Abstract..................................................................................................................................................i
Committee Membership.......................................................................................................................... iii
Foreword.................................................................................................................................................. xi
Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges ............. xiii
CLSI Reference Methods vs Commercial Methods and CLSI vs US Food and Drug
Administration Breakpoints...................................................................................................................xiv
Subcommittee on Antimicrobial Susceptibility Testing Mission Statement .....................................xv

Chapter 1: Introduction...........................................................................................................................1
  1.1 Scope...........................................................................................................................................1
  1.2 Background................................................................................................................................2
  1.3 Standard Precautions...................................................................................................................2
  1.4 Terminology................................................................................................................................2

Chapter 2: Indications for Performing Antimicrobial Susceptibility Tests.................................................7
  2.1 Selecting Antimicrobial Agents for Routine Testing and Reporting ...........................................8
  2.2 Routine Reports ..........................................................................................................................8
  2.3 Antimicrobial Agent Classes .....................................................................................................8
  2.4 Selection Guidelines ..................................................................................................................12
  2.5 Suggested Guidelines for Routine and Selective Testing and Reporting ....................................13

Chapter 3: Broth and Agar Dilution Antimicrobial Susceptibility Testing Process.................................15
  3.1 Antimicrobial Agents ................................................................................................................17
  3.2 Preparing Inoculum for Dilution Tests .......................................................................................19
  3.3 Agar Dilution Procedure ..........................................................................................................20
  3.4 Preparing Agar Dilution Plates .................................................................................................21
  3.5 Broth Dilution Procedures (Macrodilution and Microdilution) .....................................................25
  3.6 Broth Macrodilution (Tube) Method ..........................................................................................26
  3.7 Broth Microdilution Method ......................................................................................................27
  3.8 Inoculum Suspension Colony Counts .......................................................................................30
  3.9 Determining Broth Macro- or Microdilution End Points .............................................................31
  3.10 Reporting Minimal Inhibitory Concentration Results .............................................................35
  3.11 Special Considerations for Fastidious Organisms ..................................................................35
  3.12 Special Considerations for Detecting Resistance ....................................................................40
  3.13 Supplemental (Not Routine) Tests ...........................................................................................49
  3.14 Dilution Test Method Limitations .............................................................................................50

Chapter 4: Quality Control and Quality Assurance................................................................................53
  4.1 Quality Control Purpose .............................................................................................................53
  4.2 Quality Control Responsibilities ................................................................................................54
  4.3 Selecting Strains for Quality Control ..........................................................................................54
  4.4 Maintaining and Testing Quality Control Strains ......................................................................55
  4.5 Batch or Lot Quality Control ......................................................................................................56
  4.6 Minimal Inhibitory Concentration Quality Control Ranges .........................................................56
  4.7 Quality Control Testing Frequency .............................................................................................56
  4.8 Out-of-Range Results With Quality Control Strains and Corrective Action ..............................58
  4.9 Reporting Patient Results When Out-of-Range Quality Control Results Are Observed ..........61
  4.10 Confirming Results When Testing Patient Isolates ..................................................................62
Contents (Continued)

4.11 End-Point Interpretation Control ................................................................. 62

Chapter 5: Conclusion .......................................................................................... 64

Chapter 6: Supplemental Information ................................................................. 64

References .............................................................................................................. 65

Appendix A. Preparation of Supplements, Media, and Reagents ....................... 68

Appendix B. Conditions for Dilution Antimicrobial Susceptibility Tests .......... 76

Appendix C. Quality Control Strain Maintenance ............................................... 83

Appendix D. Quality Control Protocol Flow Charts .......................................... 85

The Quality Management System Approach ...................................................... 90

Related CLSI Reference Materials ..................................................................... 91
Foreword

The most current edition of CLSI document M100, an annually published volume of tables, is made available with this standard to ensure users are aware of the latest recommendations related to the methods described in M07 and CLSI document M02.

Many other editorial and procedural changes in this edition of M07 resulted from Subcommittee on Antimicrobial Susceptibility Testing meetings held since 2015. Specific changes to the tables are summarized at the beginning of M100. The most important changes in M07 are summarized below.

Overview of Changes

This standard replaces the previous edition of the approved standard, M07-A10, published in 2015. Several changes were made in this edition, including:

- **General:**
  - Harmonized language and information on drug selection and QC with CLSI document M02
  - To harmonize with the International Organization for Standardization, the terms for the methods for inoculum preparation have been changed. “Growth method” has been changed to “broth culture method,” and “direct colony suspension method” has been changed to “colony suspension method” throughout the document

- **Subchapter 1.4.1, Definitions:**
  - Clarified definitions for breakpoint, interpretive category, susceptible, susceptible-dose dependent, intermediate, resistant, nonsusceptible, and quality control
  - Added definitions for minimal inhibitory concentration, routine test, supplemental test, surrogate agent test, CarbaNP test, and modified carbapenem inactivation method

- **Subchapter 1.4.2, Abbreviations and Acronyms:**
  - Deleted abbreviations for β-lactamase types

- **Subchapter 2.3, Antimicrobial Agent Classes:**
  - Clarified and updated antimicrobial agent classes

- **Subchapter 2.3.2.2, Folate Pathway Antagonists:**
  - Revised nomenclature from “folate pathway inhibitor” to “folate pathway antagonist”

- **Subchapter 3.9, Determining Broth Macro- or Microdilution End Points:**
  - Added photographs of growth control examples and for interpreting skipped wells

- **Subchapter 3.11, Table 1. Testing Considerations for Fastidious Organisms:**
  - Clarified source plate incubation times and inoculum broth for some fastidious organisms

- **Subchapter 3.12, Special Considerations for Detecting Resistance:**
  - Reorganized and streamlined
  - Moved Subchapters 3.12.4 (Inducible Clindamycin Resistance) and 3.12.6 (β-Lactamase Tests) to create a new subchapter, 3.13 (Supplemental [Not Routine] Tests)
• **Subchapter 3.12.1, Staphylococci:**
  – Added information for *Staphylococcus pseudintermedius* and *Staphylococcus schleiferi*
  – Reorganized and clarified information for staphylococci

• **Subchapter 3.12.4, Gram-Negative Bacilli:**
  – Expanded and clarified information on β-lactamases
  – Added footnote to Table 4, Enzyme Classifications for β-Lactamas, to clarify the difference between cephalosporin subclasses and generations
  – Updated nomenclature for *Enterobacter aerogenes* to *Klebsiella* (formerly *Enterobacter*) {aerogenes}^4

• **Subchapter 3.13.1, Inducible Clindamycin Resistance:**
  – Consolidated information from former Subchapter 3.13.1.8

• **Subchapter 4.3, Selecting Strains for Quality Control:**
  – Clarified the example in the third paragraph

• **Appendixes:**
  – Reorganized to reflect the order in which they are referenced in the main text, as follows:
    o **Appendix A. Preparation of Supplements, Media, and Reagents** (formerly Appendix B)
    o **Appendix B. Conditions for Dilution Antimicrobial Susceptibility Tests** (formerly Appendix C)
    o **Appendix C. Quality Control Strain Maintenance** (formerly Appendix E)
    o **Appendix D. Quality Control Protocol Flow Charts** (formerly Appendix A)

  – Deleted **Quality Control Strains for Antimicrobial Susceptibility Tests** (formerly Appendix D)
    (see M100² Appendix C)

• **Appendix A. Preparation of Supplements, Media, and Reagents:**
  – Reorganized procedures into step-action tables

• **Appendix C. Quality Control Strain Maintenance:**
  – Clarified maintenance and subculture of QC strains

• **Appendix D. Quality Control Protocol Flow Charts:**
  – Recreated QC flow charts in black-and-white format for easier viewing
  – Revised Appendixes D1 and D2 flow charts
Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges

The Clinical and Laboratory Standards Institute (CLSI) is an international, voluntary, not-for-profit, interdisciplinary, standards-developing, and educational organization accredited by the American National Standards Institute that develops and promotes the use of consensus-developed standards and guidelines within the health care community. These consensus standards and guidelines are developed in an open and consensus-seeking forum to cover critical areas of diagnostic testing and patient health care. CLSI is open to anyone or any organization that has an interest in diagnostic testing and patient care. Information about CLSI is found at www.clsi.org.

The CLSI Subcommittee on Antimicrobial Susceptibility Testing reviews data from a variety of sources and studies (eg, in vitro, pharmacokinetics-pharmacodynamics, and clinical studies) to establish antimicrobial susceptibility test methods, breakpoints, and QC parameters. The details of the data necessary to establish breakpoints, QC parameters, and how the data are presented for evaluation are described in CLSI document M23.5

Over time, a microorganism’s susceptibility to an antimicrobial agent may decrease, resulting in a lack of clinical efficacy and/or safety. In addition, microbiological methods and QC parameters may be refined to ensure more accurate and better performance of susceptibility test methods. Because of these types of changes, CLSI continually monitors and updates information in its documents. Although CLSI standards and guidelines are developed using the most current information available at the time, the field of science and medicine is always changing; therefore, standards and guidelines should be used in conjunction with clinical judgment, current knowledge, and clinically relevant laboratory test results to guide patient treatment.

Additional information, updates, and changes in this standard are found in the meeting summary minutes of the Subcommittee on Antimicrobial Susceptibility Testing at www.clsi.org.
CLSI Reference Methods vs Commercial Methods and CLSI vs US Food and Drug Administration Breakpoints

It is important for users of M02, M07, and the M100 supplement to recognize that the standard methods described in CLSI documents are reference methods. These methods may be used for routine antimicrobial susceptibility testing of patient isolates, for evaluation of commercial devices that will be used in medical laboratories, or by drug or device manufacturers for testing of new agents or systems. Results generated by reference methods, such as those contained in CLSI documents, may be used by regulatory authorities to evaluate the performance of commercial susceptibility testing devices as part of the approval process. Clearance by a regulatory authority indicates the commercial susceptibility testing device provides susceptibility results that are substantially equivalent to results generated using reference methods for the organisms and antimicrobial agents described in the device manufacturer’s approved package insert.

CLSI breakpoints may differ from those approved by various regulatory authorities for many reasons, including use of different databases, differences in data interpretation, differences in doses used in different parts of the world, and public health policies. Differences also exist because CLSI proactively evaluates the need for changing breakpoints. The reasons why breakpoints may change and the manner in which CLSI evaluates data and determines breakpoints are outlined in CLSI document M23.

Following a decision by CLSI to change an existing breakpoint, regulatory authorities may also review data to determine how changing breakpoints may affect the safety and effectiveness of the antimicrobial agent for the approved indications. If the regulatory authority changes breakpoints, commercial device manufacturers may have to conduct a clinical trial, submit the data to the regulatory authority, and await review and approval. For these reasons, a delay of one or more years may be needed if a breakpoint and interpretive category change is to be implemented by a device manufacturer. In the United States, it is acceptable for laboratories that use US Food and Drug Administration (FDA)–cleared susceptibility testing devices to use existing FDA breakpoints. Either FDA or CLSI susceptibility breakpoints are acceptable to laboratory accrediting organizations in the United States. Policies in other countries may vary. Each laboratory should check with the manufacturer of its antimicrobial susceptibility test system for additional information on the breakpoints and interpretive categories used in its system’s software.

Following discussions with appropriate stakeholders (eg, infectious diseases and pharmacy practitioners, the pharmacy and therapeutics and infection control committees of the medical staff, and antimicrobial stewardship teams), newly approved or revised breakpoints may be implemented by laboratories. Following verification, CLSI broth dilution and agar dilution test breakpoints may be implemented as soon as they are published in M100. If a device includes antimicrobial test concentrations sufficient to allow interpretation of susceptibility and resistance to an agent using the CLSI breakpoints, a laboratory could choose to, after appropriate verification, interpret and report results using CLSI breakpoints.
Subcommittee on Antimicrobial Susceptibility Testing Mission Statement

The Subcommittee on Antimicrobial Susceptibility Testing is composed of representatives from the professions, government, and industry, including microbiology laboratories, government agencies, healthcare providers and educators, and pharmaceutical and diagnostic microbiology industries. Using the CLSI voluntary consensus process, the subcommittee develops standards that promote accurate antimicrobial susceptibility testing and appropriate reporting. The mission of the Subcommittee on Antimicrobial Susceptibility Testing is to:

- Develop standard reference methods for antimicrobial susceptibility tests.
- Provide quality control parameters for standard test methods.
- Establish breakpoints for the results of standard antimicrobial susceptibility tests and provide epidemiological cutoff values when breakpoints are not available.
- Provide suggestions for testing and reporting strategies that are clinically relevant and cost-effective.
- Continually refine standards and optimize detection of emerging resistance mechanisms through development of new or revised methods, breakpoints, and quality control parameters.
- Educate users through multimedia communication of standards and guidelines.
- Foster a dialogue with users of these methods and those who apply them.

The ultimate purpose of the subcommittee’s mission is to provide useful information to enable laboratories to assist the clinician in the selection of appropriate antimicrobial therapy for patient care. The standards and guidelines are meant to be comprehensive and to include all antimicrobial agents for which the data meet established CLSI guidelines. The values that guide this mission are quality, accuracy, fairness, timeliness, teamwork, consensus, and trust.

NOTE: The content of this standard is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

Key Words

Agar dilution, antimicrobial susceptibility, broth dilution, broth macrodilution, broth microdilution, minimal inhibitory concentration
M07, 11th ed.
Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically

Chapter 1: Introduction

This chapter includes:

- Standard’s scope and applicable exclusions
- Background information pertinent to the standard’s content
- Standard precautions information
- Terms and definitions used in the standard
- Abbreviations and acronyms used in the standard

1.1 Scope

This standard describes standard broth (macrodilution and microdilution) and agar dilution methods for determining in vitro susceptibility to antimicrobial agents for bacteria that grow aerobically and includes:

- Broth and agar dilution test preparation
- Testing conditions, including inoculum preparation and standardization, incubation time, and incubation temperature
- Reporting minimal inhibitory concentration (MIC) results
- QC procedures
- Dilution test method limitations

To assist the medical laboratory, suggestions are provided for selecting antimicrobial agents for routine testing and reporting.

Standards for testing the in vitro antimicrobial susceptibility of bacteria that grow aerobically using the antimicrobial disk testing method are found in CLSI document M02.3 Standards for testing the in vitro antimicrobial susceptibility of bacteria that grow anaerobically are found in CLSI document M11.6 Guidelines for standardized antimicrobial susceptibility testing (AST) of infrequently isolated or fastidious bacteria that are not included in CLSI documents M02,3 M07, or M116 are available in CLSI document M45.7 The AST methods provided in this standard can be used in laboratories around the world including but not limited to:

- Medical laboratories
- Public health laboratories
- Research laboratories
- Food laboratories
- Environmental laboratories
1.2 Background

Either broth or agar dilution methods may be used to quantitatively measure the \textit{in vitro} activity of an antimicrobial agent against a given bacterial isolate. To perform the tests, plates or a series of tubes are prepared with an agar or broth medium to which various concentrations of the antimicrobial agents are added. The plates or tubes are then inoculated with a standardized suspension of the test organism. After incubating for the appropriate time interval, the tests are read, the MIC is determined, and the results are analyzed using approved breakpoints. The final result is significantly influenced by methodology, which must be carefully controlled if reproducible results (intra- and interlaboratory) are to be achieved.

This standard describes reference broth dilution (macrodilution and microdilution) and agar dilution methods. The basic components of these methods are largely derived from information contained in published recommendations.\textsuperscript{8} Although these methods are standard reference methods, some are sufficiently practical for routine use in medical or public health laboratories.

Commercial systems based primarily or in part on some of these methods are available and may provide results essentially equivalent to the CLSI methods described. CLSI does not approve or endorse commercial products or devices.

The methods described in this standard are intended primarily for testing commonly isolated aerobic or facultative bacteria that grow well after overnight incubation in unsupplemented Mueller-Hinton agar (MHA) or Mueller-Hinton broth (MHB). Alternative media and methods for some fastidious or uncommon organisms are described in Subchapter 3.11 and M100\textsuperscript{2} Tables 2E through 2I. Methods for testing anaerobic bacteria are provided in CLSI document M11\textsuperscript{6} and in M100\textsuperscript{2} Table 2J. Methods for testing infrequently isolated or fastidious bacteria not included in CLSI documents M02\textsuperscript{3} and M07 are found in CLSI document M45.\textsuperscript{7}

This standard, along with M100,\textsuperscript{2} describes methods, QC, breakpoints, and interpretive categories currently recommended for dilution susceptibility tests. When new problems are recognized or improvements in these criteria are developed, changes will be incorporated into future editions of this standard and M100.\textsuperscript{2}

1.3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory.\textsuperscript{9} For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29,\textsuperscript{10}

1.4 Terminology

1.4.1 Definitions

\textbf{breakpoint} – minimal inhibitory concentration (MIC) or zone diameter value used to categorize an organism as susceptible, susceptible-dose dependent, intermediate, resistant, or nonsusceptible; \textbf{NOTE 1}: MIC or zone diameter values generated by a susceptibility test can be interpreted based upon established breakpoints; \textbf{NOTE 2}: See interpretive category.